Full-Time

Senior Director/Vice President

Delivery

Posted on 6/27/2024

Orbital Therapeutics

Orbital Therapeutics

51-200 employees

Develops RNA-based medicines and therapies

Biotechnology
Healthcare

Expert

Cambridge, MA, USA

Category
Bioinformatics
Genomics
Biology Lab & Research
Biology & Biotech
Requirements
  • Ph.D. in Biochemistry, Chemical Engineering, Biology, or related scientific discipline.
  • A proven scientific leader with 10+ years of industry experience.
  • Familiarity with delivery of nucleic acids is required.
  • Experience in moving technology from preclinical to clinical stages.
  • Outstanding teamwork, communication, and interpersonal skills.
  • Team leadership experience with a demonstrated track record of personnel development.
  • Ability to adapt to increasing scope and complexity of work brought on by growth/change and helps others manage through change.
Responsibilities
  • Provide leadership and strategic direction for delivery at Orbital.
  • Lead design and synthesis of novel chemical libraries to enhance delivery of nucleic acids in lipid nanoparticles.
  • Engage with CDMOs to successfully scale lead compounds.
  • Develop with expert scientists virus like particles (VLP) delivery technology.
  • Optimize delivery of nucleic acids using either LNP or VLP delivery technologies.
  • Work closely with IP to assess patentability, develop patent strategy and lead preparation of patent applications & documents.
  • Communicate scientifically rigorous findings and delivery strategy via verbal and written communications, including internal presentations to key stakeholders (e.g. Executive leadership team, Board of Directors) and external presentations.
  • Lead, teach and mentor junior staff to promote a culture of growth and learning.

Orbital Therapeutics focuses on developing RNA-based medicines, specifically targeting areas like vaccines, immunomodulation, and protein replacement. The company utilizes RNA technology, advanced delivery methods, data science, and automation to create a platform for a wide range of therapeutic applications. Unlike many competitors, Orbital Therapeutics does not work with small interfering RNA, which sets it apart in the RNA medicine space. The goal is to enhance global health by harnessing RNA medicines to treat diseases in innovative ways that were not possible before. Revenue is generated through the sale of these medicines to healthcare providers who treat patients with various conditions.

Company Stage

Series A

Total Funding

$262.6M

Headquarters

San Francisco, California

Founded

2022

Growth & Insights
Headcount

6 month growth

4%

1 year growth

0%

2 year growth

13%
Simplify Jobs

Simplify's Take

What believers are saying

  • Increased interest in RNA vaccines post-COVID-19 boosts Orbital's market potential.
  • Advancements in lipid nanoparticle delivery enhance RNA therapeutic stability and efficacy.
  • Growing personalized medicine trend aligns with Orbital's RNA-based therapy focus.

What critics are saying

  • Competition from established pharma companies may challenge Orbital's market share.
  • Regulatory scrutiny could delay clinical trials for RNA-based therapies.
  • Rapid tech advancements in RNA delivery require continuous R&D investment.

What makes Orbital Therapeutics unique

  • Orbital Therapeutics focuses on RNA-based medicines excluding small interfering RNA.
  • The company integrates RNA technology with delivery techniques, data analytics, and automation.
  • Orbital's initial focus includes vaccines, immunomodulation, and protein replacement.

Help us improve and share your feedback! Did you find this helpful?

INACTIVE